Traws Pharma Valuation
| TRAW Stock | 4.58 0.16 3.38% |
At this time, the company appears to be undervalued. Traws Pharma has a current Real Value of USD5.45 per share. The regular price of the company is USD4.58. Our model measures the value of Traws Pharma from inspecting the company fundamentals such as Return On Equity of -10.97, shares owned by insiders of 14.62 %, and Current Valuation of (8.03 M) as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Traws Pharma's valuation include:
Price Book 1.6745 | Enterprise Value -8 M | Enterprise Value Ebitda 0.3293 | Price Sales 39.1656 | Enterprise Value Revenue 1.2538 |
Undervalued
Today
Please note that Traws Pharma's price fluctuation is relatively risky at this time. Calculation of the real value of Traws Pharma is based on 3 months time horizon. Increasing Traws Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Traws stock is determined by what a typical buyer is willing to pay for full or partial control of Traws Pharma. Since Traws Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Traws Stock. However, Traws Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.58 | Real 5.45 | Target 6.5 | Hype 4.79 |
The intrinsic value of Traws Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Traws Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Traws Pharma helps investors to forecast how Traws stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Traws Pharma more accurately as focusing exclusively on Traws Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Traws Pharma's intrinsic value based on its ongoing forecasts of Traws Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Traws Pharma's closest peers.
Traws Pharma Cash |
|
Traws Valuation Trend
Analysing the historical paterns of Traws Pharma's enterprise value and its market capitalization is a good way to estimate and gauge the value of Traws Pharma over time and is usually enough for investors to make rational market timing decisions.
Traws Pharma Total Value Analysis
Traws Pharma is at this time forecasted to have valuation of (8.03 M) with market capitalization of 8.85 M, debt of 12.01 M, and cash on hands of . The negative valuation of Traws Pharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Traws Pharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(8.03 M) | 8.85 M | 12.01 M |
Traws Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Traws Pharma has an asset utilization ratio of 1.0 percent. This indicates that the Company is making USD0.009963 for each dollar of assets. An increasing asset utilization means that Traws Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Traws Pharma Ownership Allocation
Traws Pharma shows a total of 25.31 Million outstanding shares. Traws Pharma has 14.62 % of its outstanding shares held by insiders and 11.4 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Traws Pharma Profitability Analysis
The company reported the previous year's revenue of 226 K. Net Loss for the year was (18.95 M) with profit before overhead, payroll, taxes, and interest of 0.About Traws Pharma Valuation
Our relative valuation model uses a comparative analysis of Traws Pharma. We calculate exposure to Traws Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Traws Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 210 K | 199.5 K | |
| Pretax Profit Margin | (83.84) | (88.03) | |
| Operating Profit Margin | (89.81) | (94.30) | |
| Net Loss | (83.84) | (88.03) | |
| Gross Profit Margin | 0.93 | 1.03 |
Traws Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Traws Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 21 M | |
| Shares Float | 22.4 M |
Traws Pharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Traws Pharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Traws we look at many different elements of the entity such as Traws's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Traws Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Traws Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Traws Pharma's worth.Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.